AbbVie Debt Issuance Proceeds increased by 100.1% to $7.99B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.1%, from $3.99B to $7.99B.
An increase indicates successful access to capital markets for expansion or refinancing, while a decrease may suggest a focus on deleveraging or limited market access.
This metric tracks the total cash proceeds received from the issuance of long-term or short-term debt instruments. It re...
Large-cap companies frequently issue debt to optimize their cost of capital; peers monitor this to maintain investment-grade credit ratings.
debt_issuance| Q3 '21 | Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00B | $2.00B | $0.00 | $0.00 | $0.00 | $0.00 | $14.96B | $2.00B | $3.99B | $7.99B |
| QoQ Change | — | +100.0% | -100.0% | — | — | — | — | -86.6% | +99.7% | +100.1% |
| YoY Change | — | — | -100.0% | — | — | — | — | — | -73.3% | +100.1% |